CanSense: Funding, Investors & Team (Sep 2026)
CanSense is a company that creates a low-cost and adaptable blood examination designed to detect bowel cancer at an early stage.
CanSense has raised $1.6M across 1 funding round on record, the most recent a Seed of $1.6M announced in Mar 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CanSense Company Profile and Key Stats
Latest funding round on record: Mar 2023.
CanSense Funding Rounds
CanSense Founders and Leadership Team
No contact details are on record for this team yet.
CanSense Funding Compared to Other Biotechnology Startups
CanSense's latest round of $1.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CanSense in Biotechnology and Swansea
Companies Similar to CanSense
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
CanSense Funding FAQs
What does CanSense do?
CanSense is a company that creates a low-cost and adaptable blood examination designed to detect bowel cancer at an early stage.
How much funding has CanSense raised?
CanSense has raised $1.6M across 1 round on record. The most recent is a Seed of $1.6M announced in Mar 2023.
When did CanSense last raise funding?
CanSense's most recent funding round on record is a Seed of $1.6M, announced in Mar 2023.
Who founded CanSense?
FundedIQ lists Peter Dunstan (Founder) at CanSense.
Where is CanSense headquartered?
CanSense is based in Swansea, United Kingdom.
How many employees does CanSense have?
CanSense is in the 1-10 employee band.
How does CanSense's funding compare to other Biotechnology startups?
CanSense's latest round of $1.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's CanSense Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CanSense is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.